Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Recurrent Acute Biphenotypic LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Biphenotypic LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Decitabine and Cedazuridine

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER